- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07942285
Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5
Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Patients With PD-L1 CPS <5 Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled, Multicenter, Phase III Clinical Study
This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5.
Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Tianjin, Kina, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Ta kontakt med:
- Ting Deng
- Telefonnummer: +86 8008180388
- E-post: xymcdengting@126.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Affiliated Drum Tower Hospital, Medical School of Nanjing University
-
Ta kontakt med:
- Jia Wei
- Telefonnummer: +86 25 8310 6666
- E-post: jiawei99@nju.edu.cn
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- West China Hospital, Sichuan University
-
Ta kontakt med:
- Hongfeng Gou
- Telefonnummer: +86-28-85422114
- E-post: joan_gou1977@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Aged 18-75 years.
- Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma without prior systemic therapy.
- HER2-negative status.
- At least one measurable or evaluable lesion per RECIST v1.1.
- PD-L1 CPS <5, assessed using the PD-L1 IHC 22C3 assay on pretreatment tumor tissue and confirmed by a local or central laboratory.
- ECOG PS 0-1
- Life expectancy ≥3 months.
Exclusion Criteria:
- Pregnant or breastfeeding women, or those planning pregnancy within 6 months after treatment.
- Active tumor bleeding.
- Severe gastrointestinal obstruction or difficulty swallowing tablets.
- Unresolved Grade >1 toxicity from prior anticancer therapy, with protocol-defined exceptions.
- Known DPD deficiency or prior Grade ≥3 fluoropyrimidine-related mucosal toxicity.
- Grade ≥3 hypersensitivity to monoclonal antibodies or chemotherapy components.
- History of seizures, CNS metastases, spinal cord compression, or meningeal metastases.
- Clinically significant cardiovascular or cerebrovascular disease.
- History of severe toxicity requiring permanent discontinuation of immune checkpoint inhibitors or study-related treatment.
- History of noninfectious enteritis requiring corticosteroids within 1 year before treatment.
- Uncontrolled bleeding, bleeding tendency, severe non-healing wounds, ulcers, fractures, or high-risk varices or portal hypertension.
- Intestinal obstruction within 28 days before treatment, unless surgically resolved or completely recovered.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental Arm
Sintilimab Plus Ipilimumab N01 and Chemotherapy |
Patients in the experimental arm will receive a single dose of ipilimumab N01 (3 mg/kg IV), combined with sintilimab (200 mg IV, Q3W) and XELOX or SOX chemotherapy for 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. Subsequent dosing of ipilimumab N01 will be determined based on radiological assessments per RECIST v1.1 and safety evaluations. |
|
Aktiv komparator: Active Comparator
Sintilimab Plus Chemotherapy |
Patients in the active comparator arm will receive sintilimab (200 mg IV, Q3W) plus XELOX or SOX chemotherapy for up to 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: From randomization to death from any cause, assessed up to 48 months.
|
Defined as the time from randomization to death from any cause |
From randomization to death from any cause, assessed up to 48 months.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: From baseline to disease progression, assessed up to 24 months.
|
PFS is defined as the time from randomization to the first disease progression per RECIST v1.1 or death from any cause, whichever occurs first. |
From baseline to disease progression, assessed up to 24 months.
|
|
Objective Response Rate (ORR)
Tidsramme: From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.
|
ORR is defined as the percentage of response-evaluable participants with measurable disease at baseline who achieve a best overall response of confirmed complete response (CR) or partial response (PR) per RECIST v1.1. |
From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.
|
|
Incidence of Adverse Events (AEs)
Tidsramme: From the first dose through the protocol-defined safety follow-up period, up to 48 months
|
Percentage of participants experiencing AEs, including severity and relationship to study treatment. |
From the first dose through the protocol-defined safety follow-up period, up to 48 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2026-1221-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .